[go: up one dir, main page]

MX2009011358A - Derivados de pirimidinona y metodos para su uso. - Google Patents

Derivados de pirimidinona y metodos para su uso.

Info

Publication number
MX2009011358A
MX2009011358A MX2009011358A MX2009011358A MX2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A
Authority
MX
Mexico
Prior art keywords
methods
pyrimidinone derivatives
pyrimidinone
derivatives
gpr119
Prior art date
Application number
MX2009011358A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Jinsong Hao
Hong Liu
Craig D Boyle
Unmesh G Shah
Bernard R Neustadt
Andrew W Stamford
Santhosh Francis Neelamkavil
Joel Harris
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009011358A publication Critical patent/MX2009011358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a Derivados de Pirimidinona, composiciones caracterizado además porque comprenden un Derivado de Pirimidinona, y métodos de uso de los Derivados de Pirimidinona para tratar o prevenir la obesidad, diabetes, un trastorno metabólico, una enfermedad cardiovascular o un trastorno relacionado con la actividad del receptor 119 acoplado a la proteína G ("GPR119") en un paciente.
MX2009011358A 2007-04-20 2008-04-17 Derivados de pirimidinona y metodos para su uso. MX2009011358A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92545007P 2007-04-20 2007-04-20
US95334207P 2007-08-01 2007-08-01
PCT/US2008/004933 WO2008130581A1 (en) 2007-04-20 2008-04-17 Pyrimidinone derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009011358A true MX2009011358A (es) 2009-11-05

Family

ID=39655056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011358A MX2009011358A (es) 2007-04-20 2008-04-17 Derivados de pirimidinona y metodos para su uso.

Country Status (11)

Country Link
US (1) US20100190687A1 (es)
EP (1) EP2148869A1 (es)
JP (1) JP2010524940A (es)
CN (1) CN102015677A (es)
AR (1) AR066121A1 (es)
CA (1) CA2684633A1 (es)
CL (1) CL2008001126A1 (es)
MX (1) MX2009011358A (es)
PE (1) PE20090151A1 (es)
TW (1) TW200900403A (es)
WO (1) WO2008130581A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078719A4 (en) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
JP2012518597A (ja) * 2009-02-23 2012-08-16 Ｍｓｄ株式会社 ピリミジン−４（３ｈ）−オン誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
CN102234287B (zh) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN102464661B (zh) * 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9777005B2 (en) 2012-11-19 2017-10-03 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound containing a substituted pyrrole ring
JP2016222621A (ja) * 2015-06-02 2016-12-28 学校法人九州文化学園 メラニン合成促進組成物
PE20180694A1 (es) * 2015-07-31 2018-04-23 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il-carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il-carbamato como inhibidores de magl
CN110382479A (zh) 2017-01-20 2019-10-25 辉瑞大药厂 作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
RU2726631C1 (ru) 2017-01-23 2020-07-15 Пфайзер Инк. Гетероциклические спиросоединения в качестве ингибиторов magl
CN110452157B (zh) * 2018-12-28 2020-11-03 广州市朗启医药科技有限责任公司 常山酮及其中间体的合成方法
CR20210482A (es) * 2019-03-14 2021-11-09 Janssen Sciences Ireland Unlimited Co Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
WO2021245426A1 (en) * 2020-06-05 2021-12-09 Pathios Therapeutics Limited N-(phenylaminocarbonyl) tetrahydro-isoquinolines and related compounds as modulators of gpr65
GB202103704D0 (en) * 2021-03-17 2021-04-28 Pathios Therapeutics Ltd Compounds
MX2022015739A (es) * 2020-06-09 2023-03-23 Dana Farber Cancer Inst Inc Inhibidores alostericos de egfr y metodos de uso de estos.
TW202227435A (zh) * 2020-09-11 2022-07-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物
CA3197470A1 (en) 2020-10-21 2022-04-28 Aligos Therapeutics, Inc. Bicyclic compounds
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2025137307A1 (en) * 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
US5240938A (en) * 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
US5264439A (en) * 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5409926A (en) * 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US20030180813A1 (en) * 2000-12-01 2003-09-25 Takahide Ohishi Method of screening remedy for diabetes
CN1751038A (zh) * 2003-02-24 2006-03-22 艾尼纳制药公司 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
EP1951244A4 (en) * 2005-11-22 2010-08-25 Glaxosmithkline Llc CALCILYTIC COMPOUNDS
EP2078719A4 (en) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
EP2148869A1 (en) 2010-02-03
CL2008001126A1 (es) 2008-10-24
CA2684633A1 (en) 2008-10-30
AR066121A1 (es) 2009-07-22
JP2010524940A (ja) 2010-07-22
US20100190687A1 (en) 2010-07-29
WO2008130581A1 (en) 2008-10-30
CN102015677A (zh) 2011-04-13
TW200900403A (en) 2009-01-01
PE20090151A1 (es) 2009-02-26

Similar Documents

Publication Publication Date Title
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
IL193996A0 (en) Neuromedin u receptor agonists and uses thereof
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
IL243574B (en) A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
PL1957484T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i zastosowanie w lecznictwie
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
MX2009000900A (es) Derivados de imidazolonas sustituidas, preparacion y usos.
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
JO2645B1 (en) Vehicles
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
EA201190209A1 (ru) Соединения для лечения метаболических расстройств